Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.26
IMMU's Cash to Debt is ranked lower than
85% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. IMMU: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
IMMU' s Cash to Debt Range Over the Past 10 Years
Min: 0.26  Med: 5380.65 Max: No Debt
Current: 0.26
Equity to Asset -1.00
IMMU's Equity to Asset is ranked lower than
96% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IMMU: -1.00 )
Ranked among companies with meaningful Equity to Asset only.
IMMU' s Equity to Asset Range Over the Past 10 Years
Min: -1  Med: 0.72 Max: 0.92
Current: -1
-1
0.92
F-Score: 3
Z-Score: -10.22
M-Score: -2.29
WACC vs ROIC
10.07%
-499.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1825.18
IMMU's Operating margin (%) is ranked lower than
78% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. IMMU: -1825.18 )
Ranked among companies with meaningful Operating margin (%) only.
IMMU' s Operating margin (%) Range Over the Past 10 Years
Min: -1825.18  Med: -289.05 Max: 55.69
Current: -1825.18
-1825.18
55.69
Net-margin (%) -1826.07
IMMU's Net-margin (%) is ranked lower than
77% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. IMMU: -1826.07 )
Ranked among companies with meaningful Net-margin (%) only.
IMMU' s Net-margin (%) Range Over the Past 10 Years
Min: -1826.07  Med: -212.6 Max: 60.72
Current: -1826.07
-1826.07
60.72
ROA (%) -73.04
IMMU's ROA (%) is ranked lower than
76% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. IMMU: -73.04 )
Ranked among companies with meaningful ROA (%) only.
IMMU' s ROA (%) Range Over the Past 10 Years
Min: -74.26  Med: -32.8 Max: 74.44
Current: -73.04
-74.26
74.44
ROC (Joel Greenblatt) (%) -294.92
IMMU's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. IMMU: -294.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMMU' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2222.63  Med: -265.32 Max: 760.43
Current: -294.92
-2222.63
760.43
Revenue Growth (3Y)(%) -19.00
IMMU's Revenue Growth (3Y)(%) is ranked lower than
95% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. IMMU: -19.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMMU' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.9  Med: 2.9 Max: 81.6
Current: -19
-56.9
81.6
EBITDA Growth (3Y)(%) 66.30
IMMU's EBITDA Growth (3Y)(%) is ranked lower than
100% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. IMMU: 66.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMMU' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.2  Med: -7.4 Max: 66.3
Current: 66.3
-26.2
66.3
EPS Growth (3Y)(%) 60.50
IMMU's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. IMMU: 60.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMMU' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.7  Med: -12.6 Max: 88
Current: 60.5
-37.7
88
» IMMU's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

IMMU Guru Trades in

Q2 2015

IMMU Guru Trades in Q2 2015

Paul Tudor Jones 17,600 sh (New)
» More
Q3 2015

IMMU Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

IMMU Guru Trades in Q2 2016

Jim Simons 1,772,807 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PTCT, NAS:SQNM, OTCPK:NICXF, NAS:FOMX, NAS:IMGN, NAS:BSTC, NAS:AGTC, NAS:EDGE, NAS:CRVS, OTCPK:GNIXF, NAS:NLNK, NAS:PRTK, OTCPK:ELVAF, NAS:RXDX, NAS:AKBA, NAS:ESPR, NAS:CNCE, NAS:IDRA, NAS:NVIV, NAS:SGMO » details
Traded in other countries:IM3.Germany,
Immunomedics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes two antibody-drug conjugates sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all autoimmune disease indications. It manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Its geographic locations include United States and Europe. It competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, ImmunoGen Merck Serono, Genmab, Celgene, Amgen, Bristol-Myers Squibb, Bayer Healthcare Pharmaceuticals, Pfizer, AstraZeneca and Eli Lilly, are engaged in the development of therapeutic autoimmune and oncology products. Its patents include approximately 267 active patents in the U.S. and more than 400 other issued patents all over the world. Its research and development activities, including testing in laboratory animals and in humans, its manufacture of antibodies, as well as the handling, labeling and storage of the product candidates that the company is developing, are all subject to stringent regulation, by the FDA in the U.S. and by comparable authorities in other countries.

Ratios

vs
industry
vs
history
P/S 81.18
IMMU's P/S is ranked lower than
79% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. IMMU: 81.18 )
Ranked among companies with meaningful P/S only.
IMMU' s P/S Range Over the Past 10 Years
Min: 2.96  Med: 29.81 Max: 132.94
Current: 81.18
2.96
132.94
EV-to-EBIT -6.95
IMMU's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. IMMU: -6.95 )
Ranked among companies with meaningful EV-to-EBIT only.
IMMU' s EV-to-EBIT Range Over the Past 10 Years
Min: -343.7  Med: -6.9 Max: 298.3
Current: -6.95
-343.7
298.3
EV-to-EBITDA -7.04
IMMU's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. IMMU: -7.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMMU' s EV-to-EBITDA Range Over the Past 10 Years
Min: -226.2  Med: -7.2 Max: 393.3
Current: -7.04
-226.2
393.3
Current Ratio 3.43
IMMU's Current Ratio is ranked higher than
52% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. IMMU: 3.43 )
Ranked among companies with meaningful Current Ratio only.
IMMU' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 4.39 Max: 11.92
Current: 3.43
0.6
11.92
Quick Ratio 3.41
IMMU's Quick Ratio is ranked higher than
54% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. IMMU: 3.41 )
Ranked among companies with meaningful Quick Ratio only.
IMMU' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 4.29 Max: 11.63
Current: 3.41
0.59
11.63
Days Inventory 134.42
IMMU's Days Inventory is ranked lower than
86% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. IMMU: 134.42 )
Ranked among companies with meaningful Days Inventory only.
IMMU' s Days Inventory Range Over the Past 10 Years
Min: 134.42  Med: 310.77 Max: 938.67
Current: 134.42
134.42
938.67
Days Sales Outstanding 58.03
IMMU's Days Sales Outstanding is ranked higher than
64% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. IMMU: 58.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMMU' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.57  Med: 24.8 Max: 105.77
Current: 58.03
2.57
105.77
Days Payable 1.00
IMMU's Days Payable is ranked lower than
99.99% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. IMMU: 1.00 )
Ranked among companies with meaningful Days Payable only.
IMMU' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 1684.86 Max: 4523.25
Current: 1
1
4523.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
IMMU's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. IMMU: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMMU' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.6  Med: -5 Max: -0.1
Current: -5
-14.6
-0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.74
IMMU's Price/Median PS Value is ranked lower than
82% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. IMMU: 2.74 )
Ranked among companies with meaningful Price/Median PS Value only.
IMMU' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.08 Max: 7.27
Current: 2.74
0.13
7.27
Earnings Yield (Greenblatt) (%) -14.40
IMMU's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. IMMU: -14.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMMU' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.4  Med: 5 Max: 18.5
Current: -14.4
-14.4
18.5

More Statistics

Revenue (TTM) (Mil) $3.23
EPS (TTM) $ -0.62
Beta1.61
Short Percentage of Float31.99%
52-Week Range $1.50 - 5.44
Shares Outstanding (Mil)95.87
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Immunomedics Inc. Reports Operating Results (10-K) Aug 27 2009 
Immunomedics Inc. Reports Operating Results (10-Q) May 11 2009 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL... Aug 19 2016
IMMUNOMEDICS INC Files SEC form 10-K, Annual Report Aug 18 2016
Edited Transcript of IMMU earnings conference call or presentation 17-Aug-16 9:00pm GMT Aug 18 2016
IMMUNOMEDICS ANNOUNCES FISCAL 2016 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Aug 18 2016
PRECLINICAL STUDY ON ENHANCING SACITUZUMAB GOVITECAN (IMMU-132) ACTIVITY IN SN-38-RESISTANT CANCER... Aug 18 2016
Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer... Aug 18 2016
Immunomedics reports 4Q loss Aug 17 2016
Immunomedics reports 4Q loss Aug 17 2016
IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 17 2016
Immunomedics Announces Fiscal 2016 Results and Clinical Program Developments Aug 17 2016
Q4 2016 Immunomedics Inc Earnings Release - After Market Close Aug 17 2016
Immunomedics Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2016 Financial... Aug 11 2016
DEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Immunomedics... Aug 08 2016
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Aug 08 2016
IMMUNOMEDICS 72 HOUR DEADLINE ALERT: APPROXIMATELY 72 HOURS REMAIN; FORMER LOUISIANA ATTORNEY... Aug 05 2016
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Aug 05 2016
APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Immunomedics... Aug 04 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of a Class... Aug 03 2016
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of a Class Action against... Aug 03 2016
AUGUST 8, 2016 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)